[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359

Phase 1/2Recruiting
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Ductal Adenocarcinoma

Conditions

Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma

Trial Timeline

Apr 28, 2025 โ†’ May 28, 2032

About [203Pb]Pb-PSV359 + [212Pb]Pb-PSV359

[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359 is a phase 1/2 stage product being developed by Perspective Therapeutics for Pancreatic Ductal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06710756. Target conditions include Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06710756Phase 1/2Recruiting

Competing Products

20 competing products in Pancreatic Ductal Adenocarcinoma

See all competitors